APGE vs. VCEL, KYMR, TWST, RXRX, CGON, DNA, DNLI, BEAM, FUSN, and INBX
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Vericel (VCEL), Kymera Therapeutics (KYMR), Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), Ginkgo Bioworks (DNA), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), and Inhibrx (INBX). These companies are all part of the "biological products, except diagnostic" industry.
Vericel (NASDAQ:VCEL) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
Vericel has higher revenue and earnings than Apogee Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vericel received 320 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 62.34% of users gave Vericel an outperform vote.
79.0% of Apogee Therapeutics shares are held by institutional investors. 7.2% of Vericel shares are held by insiders. Comparatively, 36.1% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Vericel had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 30 mentions for Vericel and 27 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.65 beat Vericel's score of 0.47 indicating that Vericel is being referred to more favorably in the media.
Vericel presently has a consensus target price of $46.80, suggesting a potential downside of 5.28%. Apogee Therapeutics has a consensus target price of $73.00, suggesting a potential upside of 36.96%. Given Vericel's higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Vericel.
Vericel has a net margin of 0.22% compared to Vericel's net margin of 0.00%. Apogee Therapeutics' return on equity of 0.21% beat Vericel's return on equity.
Summary
Vericel beats Apogee Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
